TVRD
Tvardi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.86
−2.73%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 7.1M | 21.0M | 41.9M |
| Cost of Revenue | — | 95.0K | 812.0K | 6.4M | 7.5M |
| Gross Profit | — | (95.0K) | 6.3M | 14.5M | 34.4M |
| Operating Expenses | |||||
| R&D Expense | 18.0M | 18.0M | 32.8M | 108.4M | 91.8M |
| SG&A Expense | 9.2M | 8.7M | 26.4M | 27.6M | 30.1M |
| General & Admin Expense | 9.1M | 8.7M | — | — | — |
| Selling & Marketing Expense | 137.0K | — | — | — | — |
| Other Expenses | — | — | 3.0M | — | — |
| Total Operating Expenses | 27.2M | 26.7M | 62.1M | 136.0M | 121.9M |
| Cost and Expenses | 27.2M | 26.7M | 62.9M | 142.5M | 129.4M |
| Operating Income (EBIT) | (27.2M) | (26.7M) | (55.8M) | (121.5M) | (87.5M) |
| Non-Operating | |||||
| Interest Income | 1.1M | 1.4M | 2.8M | 1.3M | 654.0K |
| Interest Expense | — | — | 8.5M | — | 3.0K |
| Net Interest Income | 1.1M | 1.4M | (5.6M) | 1.3M | 651.0K |
| Other Non-Op Income/Expense | 1.1M | 8.5M | (15.5M) | 3.0M | 2.1M |
| Non-Operating Income (excl Interest) | (970.0K) | (8.5M) | 7.0M | (3.6M) | (2.1M) |
| EBT (Pre-Tax Income) | (26.1M) | (18.2M) | (71.3M) | (118.5M) | (85.5M) |
| Income Tax Expense | — | — | (398.0K) | — | — |
| Bottom Line | |||||
| Net Income | (26.1M) | (18.2M) | (70.9M) | (118.5M) | (85.5M) |
| Earnings from Cont. Ops | (26.1M) | (18.2M) | (70.9M) | (118.5M) | (85.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (26.1M) | (25.4M) | (70.9M) | (118.5M) | (85.5M) |
| Per Share | |||||
| Basic EPS | ($2.79) | ($2.46) | ($46.59) | ($1.85) | ($2.20) |
| Diluted EPS | ($2.79) | ($3.26) | ($46.59) | ($1.85) | ($2.20) |
| Revenue Per Share | $0.00 | $0.00 | $4.69 | $2.24 | $4.48 |
| Shares | |||||
| Basic Shares Outstanding | 9.4M | 7.4M | 1.5M | 9.4M | 9.4M |
| Diluted Shares Outstanding | 9.4M | 7.8M | 1.5M | 9.4M | 9.4M |
| Profitability Metrics | |||||
| EBITDA | (26.1M) | (18.1M) | (62.6M) | (117.7M) | (85.4M) |
| D&A | 95.0K | 95.0K | 192.0K | 259.0K | 85.0K |
| EBIT | (26.2M) | (18.2M) | (62.8M) | (117.9M) | (85.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026